The objective of this study was to assess the bioequivalence of two Roxane lithium carbonate
450 mg extended release tablet formulations compared to GlaxoSmithKline's Eskalith CR 450 mg
extended release tablet under fed conditions using a single-dose, randomized,
three-treatment, three-period, six-sequence crossover design.
- No clinically significant abnormal findings on the physical examination, medical
history, or clinical laboratory results during screening.
- Participation in a clinicl trial within 30 days prior to study initiation.
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.